investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma
Mark B Faries
30 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Collaborator from Stony Brook University
Stony Brook University
Stony Brook, United States
Collaborator from Pennsylvania State College
Pennsylvania State University
State College, United States
Collaborator from Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
New York, United States
Collaborator from Columbia University
Columbia University
New York, United States
Tiina Jahkola
Helsinki University Central Hospital
Helsinki, Finland
Sergi Vidal-Sicart
Hospital Clinic of Barcelona
Barcelona, Spain
Schlomo Schneebaum
Tel Aviv University
Tel Aviv, Israel
Reinhard Dummer
University Hospital of Zurich
Zurich, Switzerland
University of Zurich
Zurich, Switzerland
Peter Hersey
University of Newcastle Australia
Newcastle, Australia
Patrick Terheyden
University Hospital Schleswig-Holstein
Lübeck, Germany
Nicola Mozzillo
Istituto Nazionale dei Tumori (IRCCS)
Milan, Italy
Michael Henderson
Peter MacCallum Cancer Centre
Melbourne, Australia
Maurice Matter
University Hospital of Lausanne
Lausanne, Switzerland
Marc Moncrieff
Norfolk and Norwich University Hospital
Norwich, United Kingdom
B Mark Smithers
Princess Alexandra Hospital
Brisbane, Australia
John Thompson
Melanoma Institute Australia
Sydney, Australia
Harald Hoekstra
University of Groningen
Groningen, Netherlands
Gregory Mckinnon
Foothills Medical Centre
Calgary, Canada
Anja Gesierich
University of Würzburg
Wurzburg, Germany
Frances Wright
Sunnybrook Health Science Centre
Toronto, Canada
Erwin Schultz
Nuremberg Hospital
Nuremberg, Germany
Show more
Related projects
Myles G Cockburn
An Innovative, Curriculum-Based Integrated Sun Exposure Behavior Intervention for
Melanoma of skin
Pathology
Charles J Dimitroff
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
Melanoma of skin
Pathology
Nancy E Thomas
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis
Melanoma of skin
Pathology
Craig Lee Slingluff
Melanoma Vaccine for Helper T Cells Combined with Targeted or Immune Therapies
Melanoma of skin
Pathology
John B Sunwoo
(PQB2) Identification of Tumor-Derived Activators of Anti-Cancer Immune Responses
Melanoma of skin
Pathology
Meenhard F Herlyn
The Role of Genetic Susceptibility in Melanoma Development
Melanoma of skin
Pathology
Harvey Mcmahon
Membrane curvature as an organizing principle for eukaryotic cell biology
Melanoma of skin
Pathology
Samuel Marguerat
Quantitative Gene Expression
Melanoma of skin
Pathology
Waldemar Priebe
Targeting Resistance to BRAF Inhibitors with WP760, a Melanoma Selective Agent
Melanoma of skin
Pathology
Show more
